Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

KALA
KALA BIO, Inc. Common Stock
stock NASDAQ

At Close
May 8, 2025 3:59:30 PM EDT
3.39USD-1.736%(-0.06)250,371
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 7, 2025 9:03:30 AM EDT
3.45USD+0.003%(+0.00)0
After-hours
Dec 31, 1969 7:00:00 PM EST
0.00USD0.000%(0.00)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 17, 2021
04:01PM EST  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Companys 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).   GlobeNewswire Inc
Nov 24, 2021
03:03PM EST  Kala Pharma 13D Filing From Mark Blumenkranz Shows Activist Stake On 7.4% In Co.   Benzinga
Nov 18, 2021
04:01PM EST  Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Companys 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).   GlobeNewswire Inc
Nov 15, 2021
11:11AM EST  Kala Sees Submitting Investigational New Drug Application To FDA For KPI-012; Subject To Regulatory Clearance, Sees Initiating Phase 2/3 Trial For Persistent Corneal Epithelial Defect In Q3'22   Benzinga
11:10AM EST  Kala Pharmaceuticals Q3 EPS $(0.43), Inline, Sales $3.10M Miss $5.16M Estimate   Benzinga
11:10AM EST  Kala Pharma Reports Purchase Of Combangio For $5M In Cash Plus ~7.79M Kala Shares, Total Value ~$16.1M   Benzinga
11:07AM EST  Earnings Scheduled For November 15, 2021   Benzinga
10:37AM EST  The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More   Benzinga
08:47AM EST  -- Achieved $3.1Million in Net Revenue in 3Q 2021 --- EYSUVIS Prescriptions Increased by 19% Compared to 2Q 2021-- Expanding Clinical-Stage Pipeline Through Acquisition of Combangio --- Conference Call and Webcast at 10:30 a.m. ET --   GlobeNewswire Inc
08:45AM EST  Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline   GlobeNewswire Inc
07:00AM EST  Kala Pharmaceuticals Announces Time Change for Third Quarter 2021   GlobeNewswire Inc
Nov 12, 2021
10:58AM EST  A Preview Of Kala Pharmaceuticals's Earnings   Benzinga
Nov 11, 2021
08:00AM EST  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in November 2021:   GlobeNewswire Inc
Nov 8, 2021
04:01PM EST  Kala Pharmaceuticals to Report Third Quarter 2021 Financial   GlobeNewswire Inc
Oct 22, 2021
04:01PM EDT  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Companys 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).   GlobeNewswire Inc
Oct 18, 2021
08:00AM EDT  Kala Pharmaceuticals Announces Appointment of C. Daniel Myers to   GlobeNewswire Inc
Oct 12, 2021
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Oct 1, 2021
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
Sep 21, 2021
04:01PM EDT  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Companys 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).   GlobeNewswire Inc
Sep 7, 2021
08:00AM EDT  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in September 2021:   GlobeNewswire Inc
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 18, 2021
04:01PM EDT  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Companys 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).   GlobeNewswire Inc
Aug 6, 2021
10:06AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 6, 2021   Benzinga
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
06:37AM EDT  HC Wainwright & Co. Maintains Buy on Kala Pharmaceuticals, Lowers Price Target to $11   Benzinga
05:56AM EDT  JP Morgan Downgrades Kala Pharmaceuticals to Neutral   Benzinga
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
07:46AM EDT  Kala Pharmaceuticals Q2 EPS $(0.57) Misses $(0.45) Estimate, Sales $3.10M Miss $5.33M Estimate   Benzinga
07:00AM EDT  -- EYSUVIS Prescriptions Increased by 93% Compared to First Quarter of 2021 --- Further Expanded Commercial Coverage for EYSUVIS to More Than 96 Million Lives --- Achieved $3.1Million in Net Revenue in Second Quarter of 2021 --- Conference Call and Webcast at 8:00 a.m. ET --   GlobeNewswire Inc
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Aug 4, 2021
08:00AM EDT  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in August.   GlobeNewswire Inc
Aug 1, 2021
11:19AM EDT  The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs   Benzinga
Jul 29, 2021
08:00AM EDT  Kala Pharmaceuticals to Report Second Quarter 2021 Financial   GlobeNewswire Inc
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 19, 2021
04:01PM EDT  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Companys 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).   GlobeNewswire Inc
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 14, 2021
07:48AM EDT  The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues   Benzinga
Jul 13, 2021
08:05AM EDT  The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data   Benzinga
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jul 7, 2021
07:41AM EDT  The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend   Benzinga
Jun 18, 2021
04:01PM EDT  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)   Business Wire
Jun 17, 2021
10:24AM EDT  Kala Pharmaceuticals Files For U.S. Patent Titled 'Biochemical binding of RET9 and VEGFR2 inhibitors'   Benzinga
Jun 3, 2021
07:00AM EDT  Kala Pharmaceuticals Announces EYSUVIS(r) Now Covered by OptumRx   Business Wire
May 27, 2021
08:00AM EDT  Kala Pharmaceuticals to Present at Jefferies 2021 Virtual Healthcare Conference   Business Wire
May 20, 2021
04:01PM EDT  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)   Business Wire
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 12, 2021
10:28AM EDT  Kala Pharmaceuticals Says Oxford Finance Provides $125M Credit Facility To Co   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
08:00AM EDT  Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference   Business Wire
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
07:32AM EDT  HC Wainwright & Co. Maintains Buy on Kala Pharmaceuticals, Lowers Price Target to $14   Benzinga
May 5, 2021
07:46AM EDT  Kala Pharmaceuticals: Q1 Earnings Insights   Benzinga
07:33AM EDT  Kala Pharmaceuticals Q1 EPS $(0.49) Beats $(0.68) Estimate, Sales $3.30M Miss $4.18M Estimate   Benzinga
07:21AM EDT  Kala Pharmaceuticals Q1 Loss Per Share $0.49 Vs Loss Per Share $0.54 Year Ago   RTTNews
07:01AM EDT  Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update   Business Wire
04:16AM EDT  Earnings Scheduled For May 5, 2021   Benzinga
May 4, 2021
10:32AM EDT  Kala Pharmaceuticals Earnings Preview   Benzinga
Apr 28, 2021
08:00AM EDT  Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call   Business Wire
Apr 13, 2021
10:10AM EDT  Kala Pharmaceuticals Granted U.S. Patent Titled 'Crystalline forms of therapeutic compounds and uses thereof'   Benzinga
Mar 30, 2021
08:06AM EDT  The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings   Benzinga
Mar 23, 2021
05:04AM EDT  Kala Pharmaceuticals Awarded U.S. Patent #10954244 Compounds and uses thereof   Benzinga
Mar 18, 2021
04:01PM EDT  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)   Business Wire
Mar 16, 2021
08:11AM EDT  Kala Pharmaceuticals Announces Preferred Position For EYSUVIS On Cigna   Benzinga
Mar 2, 2021
08:00AM EST  Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March   Business Wire
Feb 25, 2021
08:08AM EST  The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants   Benzinga
07:15AM EST  Kala Pharmaceuticals Q4 EPS $(0.55) Misses $(0.46) Estimate, Sales $2.24M Miss $2.39M Estimate   Benzinga
07:00AM EST  Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update   Business Wire
04:03AM EST  Earnings Scheduled For February 25, 2021   Benzinga
Feb 18, 2021
08:00AM EST  Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call   Business Wire
Feb 17, 2021
04:01PM EST  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)   Business Wire
Feb 16, 2021
07:14AM EST  Kala Pharma Says EYSUVIS Now Covered By Express Scripts   RTTNews
07:10AM EST  Kala Pharmaceuticals Announces EYSUVIS Now Covered By Express Scripts   Benzinga
Jan 20, 2021
04:01PM EST  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)   Business Wire
Jan 7, 2021
07:14AM EST  Kala Pharmaceuticals Announces Availability Of EYSUVISTM For The Treatment Of Dry Eye Disease   RTTNews
07:05AM EST  Kala Pharmaceuticals Announces EYSUVISTM for the Treatment of Dry Eye Disease Is Now Available In All Pharmacies   Benzinga
07:00AM EST  Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline   Business Wire
Jan 4, 2021
08:00AM EST  Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January   Business Wire
Dec 18, 2020
04:01PM EST  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)   Business Wire
Nov 16, 2020
07:23AM EST  Kala Pharma Provides Update On Launch Plans For EYSUVISTM For Dry Eye Disease   RTTNews
07:00AM EST  Kala Pharmaceuticals Provides Update on Launch Plans for EYSUVISTM for the Treatment of Dry Eye Disease   Business Wire
02:18AM EST  Four new drugs were approved by the FDA in the month of October. This compares with 11 drugs approved by the regulator last year.   RTTNews
Nov 11, 2020
08:00AM EST  Kala Pharmaceuticals to Present at the Jefferies 2020 Virtual London Healthcare Conference   Business Wire
Nov 5, 2020
09:59AM EST  Kala Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 sales results.   Benzinga
07:54AM EST  The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping   Benzinga
07:11AM EST  Kala Pharmaceuticals Q3 EPS $(0.50) Misses $(0.44) Estimate, Sales $2.22M Beat $2.01M Estimate   Benzinga
07:00AM EST  Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update   Business Wire
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 2, 2020
08:59AM EST  Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23   Benzinga
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 29, 2020
08:00AM EDT  Kala Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call   Business Wire
Oct 27, 2020
10:55AM EDT  Mid-Morning Market Update: Markets Mostly Lower; 3M Tops Q3 Estimates   Benzinga
09:50AM EDT  Kala Pharmaceuticals shares are trading higher after the company announced the FDA has approved EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease.   Benzinga
07:18AM EDT  Kala Pharma Says US FDA OKs EYSUVIS 0.25% For Short-term Treatment Of Signs And Symptoms Of Dry Eye   RTTNews
07:07AM EDT  Kala Pharma Reports FDA Approval Of EYSUVIS For Short-Term Treatment Of Signs, Symptoms Of Dry Eye Disease   Benzinga
07:00AM EDT  Kala Pharmaceuticals Announces FDA Approval of EYSUVIS(tm) for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease   Business Wire
Oct 19, 2020
04:05PM EDT  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)   Business Wire
Sep 14, 2020
02:33PM EDT  Mid-Afternoon Market Update: Dow Rises 350 Points; Cassava Sciences Shares Spike Higher   Benzinga
12:07PM EDT  Mid-Day Market Update: Immunomedics Jumps Following Acquisition News; Mallinckrodt Shares Slide   Benzinga
10:33AM EDT  Benzinga's Top Upgrades, Downgrades For September 14, 2020   Benzinga
10:27AM EDT  Mid-Morning Market Update: Markets Open Higher; Nvidia Reports $40B Deal To Buy SoftBank's Arm Holdings   Benzinga
10:19AM EDT  Shares of Kala Pharmaceuticals, Inc. (KALA) are losing almost 11 percent or $0.94 in Monday's morning trade at $7.83 after a rating downgrade by analysts at Jefferies Financial Group.   RTTNews
08:16AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
05:07AM EDT  Jefferies Downgrades Kala Pharmaceuticals to Hold, Lowers Price Target to $10   Benzinga
Sep 10, 2020
08:00AM EDT  Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for EYSUVIS(tm)   Business Wire
Sep 8, 2020
08:00AM EDT  Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September   Business Wire
Aug 6, 2020
11:21AM EDT  Kala Pharmaceuticals Earlier Reported Q2 EPS $(0.42) Misses $(0.41) Estimate, Sales $833.00K Beat $730.00K Estimate   Benzinga
07:00AM EDT  Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update   Business Wire
Aug 4, 2020
08:00AM EDT  Kala Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference   Business Wire
Jul 30, 2020
04:01PM EDT  Kala Pharmaceuticals to Report Second Quarter 2020 Financial Results and Host Conference Call   Business Wire
Jul 23, 2020
09:50AM EDT  Northland Capital Markets Initiates Coverage On Kala Pharmaceuticals with Outperform Rating, Announces Price Target of $17   Benzinga
Jul 17, 2020
04:01PM EDT  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC